Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia

Acute Myeloid Leukemia Clinical Trial

Official title:

A Phase 2/3 Prospective, Randomized, Controlled, Parallel Group Study of Intensive Therapy Combined With Venetoclax for Newly Diagnosed Adult Acute Myeloid Leukemia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05356169
• Other study ID #: IIT2021055-EC-2
• Status: Not yet recruiting
• Phase: Phase 2/Phase 3
• Start date: June 2022
• Est. completion date: June 2027

Study information

• Verified date: April 2022
• Source: Institute of Hematology & Blood Diseases Hospital
• Contact: Jianxiang Wang, Dr
• Phone: 86-22-23909120
• Email: wangjx[@]medmail.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

300 patients will be randomly distributed into the control group (n=150) and the experimental group(n=150). Patients will receive two cycles of induction chemotherapy. The control group receives standard 3+7 induction regimen containing cytarabine (100mg/m2 d1-7) and daunorubicin (60mg/m2 d1-3). The experimental group receives venetoclax combined with intensive chemotherapy (3+7 induction regimen same as the control group). For each group, patients who fail to achieve CR/CRi after two courses of induction therapy may receive alternative therapy decided by their physicians. After CR/CRi achieved, subjects proceed allo-transplantation or consolidation therapy according to their ELN risks: subjects in favorable risk group should continue with chemotherapy; subjects in poor risk group should go through transplantation; for subjects in intermediate risk group, those with suitable donors can receive transplantation while others can continue with consolidation therapy. Subjects receive 3 courses of intermediate-dose cytarabine (1.5g/m2 q12h d1, 3, 5) for age>55 years or high dose cytarabine (3g/m2 q12h d1, 3, 5) for age≤ 55 years as consolidation therapy with venetoclax in experimental group and without venetoclax in control group. After consolidation, patients will be observed.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: June 2027
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Patients with newly diagnosed AML (except for APL subtype) according to 2016 World Health Organization (WHO) classification and have not received chemotherapy before.

2. Age =18 years and =65 years.

3. Patient considered eligible for intensive chemotherapy.

4. Eastern Cooperative Oncology Group (ECOG) performance status = 2 at randomization.

5. Adequate renal function as evidenced by serum creatinine = 2.0 × upper limit of norm (ULN) or creatinine clearance >40 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR).

6. Adequate hepatic function as evidenced by:(1) Serum total bilirubin = 1.5 × ULN unless considered due to Gilbert's disease, or leukemic involvement following approval by the Coordinating Investigator or Trial Coordinator;(2) Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) = 2.5 × ULN, unless considered due to leukemic involvement following approval by the Coordinating Investigator or Trial Coordinator;(3)Myocardial enzyme<2.0×upper limit normal;(4)Left ventricular ejection fraction are within the normal range by measure of echocardiogram (ECHO)

7. No prior chemotherapy for AML except hydroxyurea for up to 14 days during the diagnostic screening phase for the control of peripheral leukemic blasts in patients with leukocytosis (e.g., white blood cell [WBC] counts > 25x109/L).

8. Able to understand and willing to sign an informed consent form (ICF).

Exclusion Criteria:

1. AML with BCR-ABL1; or myeloid blast crisis of CML.

2. Subjects who have received a prior treatment for AML with chemotherapy , hypomethylating agents or venetoclax before.

3. Subjects with acute panmyelosis with myelofibrosis or myeloid sarcoma defined by WHO 2016.

4. Subjects with a prior history of MDS, MPN or MDS/MPN.

5. Subjects with other concurrent malignant tumors on treatment with the exception of basal or squamous cell carcinoma of the skin,carcinoma in situ of the cervix, carcinoma in situ of the breast, incidental histologic finding of prostate cancerand need treatment.

6. Pregnant or lactating women.

7. Active heart disease, defined as anyone of the followings:(1) Uncontrolled or symptomatic angina pectoris;(2) A myocardial infarction 6 months before enrolled; (3)Arrhythmia needed medication or with severe clinical symptoms;(4)Uncontrolled or symptomatic congestive heart failure (NYHA> grade 2);(5)Left ventricular ejection fraction below the lower limit of the normal range.

8. Subjects with an active, uncontrolled, systemic fungal, bacterial, or viral infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment

9. Subjects with an active viral infection caused by HIV, hepatitis B or hepatitis C virus that cannot be controlled by treatment.

10. Subjects with evidence of central nervous system leukemia before treatment.

11. Subjects with epilepsy which needs drug treatment, dementia, or other abnormal mental state that can't understand or follow the protocol.

12. Conditions that limit the ingestion or gastrointestinal absorption of orally administered drugs.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• with or without venetoclax
Bcl-2 inhibitor

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Hematology & Blood Diseases Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Event-free survival	The time from randomization to treatment failure, death from any cause or relapse after achieving CR or CRi, whichever occurs first.	up to 12 months
Secondary	Overall survival Overall survival	The time from randomization to death resulting from any cause	up to 36 months
Secondary	CR rate	The proportion of patients achieving CR after two cycles of induction chemotherapy.	up to 2 months
Secondary	Rates of remission (CR/CRi) without measurable residual disease (CRMRD-)	The proportion of AML patients achieving CR/CRi with negativity for a genetic marker by real-time quantitative polymerase chain reaction and/or with negativity by multi-color flow cytometry.	up to 2 months
Secondary	Relapse free survival	From the date of complete remission(CR) until the date of documented relapse or death due to any cause or the last follow-up day.	up to 36 months
Secondary	Cumulative incidence of relapse	Calculated from tdate of first CR to the date of relapse, considering nonrelapse mortality (NRM) as a competing event	up to 36 months
Secondary	Frequency and severity of AEs	Adverse clinical events in the course of drug treatment according to CTCAE v5.0.	up to 8 months